Cowen & Co. Keeps a Buy Rating on Epizyme (EPZM)

By Carrie Williams

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZMResearch Report), with a price target of $18. The company’s shares opened today at $12.76.

According to TipRanks.com, Werber is ranked #383 out of 5203 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $20.86 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.40 and a one-year low of $5.14. Currently, Epizyme has an average volume of 854.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Develops therapeutics for the treatment of patients with genetically defined cancers